Tag: IFX

New Health Canada Licences: Quantum Blue® Infliximab Assay, IBDoc®,CALEX® Cap

BUHLMANN Diagnostics Corp (BDC), BÜHLMANN Laboratories AG’s North American affiliate is proud to announce that three of its novel products, Quantum Blue® Infliximab Assay, IBDoc® and CALEX®Cap have received Medical Device Licences from Health Canada and are now commercially available in Canada. Quantum Blue® Infliximab® and CALEX® CAP devices were approved as Class II medical
Continue Reading

Proactive Therapeutic Drug Monitoring of Infliximab: A Comparative Study of a New Point-of-Care Quantitative Test with Two Established ELISA Assays

BÜHLMANN Quantum Blue® Infliximab Trough Level Assay Citation: Afonso J, Lopes S et al. Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays. Aliment Pharmacol Ther. 2016 Oct;44(7):684-92. doi: 10.1111/apt.13757. Epub 2016 Aug 10. PMID: 27507790 First Publication using our Quantum Blue® Infliximab Trough Level Assay We are very
Continue Reading
Sign Up for BUHLMANN Updates!

Enter your email and stay on top of things,